In an evening filled with bubbly drinks and meditation exercises, MedReleaf (TSX:LEAF) gave investors a closer look at its plans for the recreational cannabis market by officially launching its second consumer brand, AltaVie.

While the company is known primarily in the cannabis space for its medicinal products, it has now made its second foray into the recreational space, with a brand focusing around the concepts of wellness and mindfulness.


Linda Burlison, MedReleaf’s director of digital marketing and commercialization, told the Investing News Network why the company expanded further into the recreational component of cannabis.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

“Everything that has gone into making really top-quality cannabis that really helps medical patients, we’re bringing that same discipline and rigor and approach to the recreational side,” Burlison said.

Despite being a company already known for its focus on medical products, Burlison said she anticipates consumers being drawn to MedReleaf’s recreational brands based on the production efforts that go into its medical line.

“Once [consumers] start experiencing our products on the recreational side, while they may be for different purposes, different occasions, I think that they’ll appreciate that it’s that same core discipline.”

While MedReleaf already holds a separate recreational cannabis line, San Rafael ‘71, Burlison explained that AltaVie is meant to welcome newcomers to the cannabis space.

Burlison said AltaVie will appeal to people looking for cannabis to be an “accessible and approachable” product, something that does not scare them. She explained that San Rafael ‘71 will appeal to consumers with experience and knowledge of cannabis culture.

“I think people can really party with [marijuana], but then there’s a whole side to it where it can bring clarity to you … [and] can help you find some peace in a crazy world,” she said.

Investor takeaway

In a note to cannabis investors earlier this year, Daniel Pearlstein, cannabis analyst with Eight Capital, wrote that observers of the industry should start to seriously consider branding metrics instead of obsessing over “farming and oversimplified capacity-based metrics” when evaluating these companies.

In its initial research report on MPX Bioceuticals (CSE:MPX), Canaccord Genuity analyst Matt Bottomley echoed Pearlstein’s point on branding.

“We believe successful branding strategies and retail distribution will eventually determine industry winners,” Bottomley wrote in his note issued March 26.

Don’t forget to follow us @INN_Resource and @INN_Cannabis for real-time updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

With files from Bryan Mc Govern.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less